Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Website: xiliotx.com




Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.04 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 241.3% (LTM)

Entry Point: Share price is 135.8% higher than minimum and 95.3% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders bought company shares on $0.4 mln (1.768% of cap.)

Key Financials (Download financials)

Ticker: XLO
Share price, USD:  (+12.4%)1.18
year average price 1.7606  


year start price 3.1331 2023-05-08

max close price 3.2000 2023-05-09

min close price 0.5004 2023-12-20

current price 1.1800 2024-05-06
Common stocks: 27 392 087

Dividend Yield:  0.0%
Last revenue growth (y/y):  ---
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 32
Net Debt ($m): -157
EV (Enterprise Value): -125
Price to Book: 0.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-16Zacks Investment Research

Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why

2024-03-28InvestorPlace

Why Is Xilio Therapeutics (XLO) Stock up 168% Today?

2023-10-31GlobeNewsWire

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol XLO XLO XLO XLO XLO XLO
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-04-01 2023-11-09 2023-08-14 2023-05-09 2023-03-02 2022-11-09
acceptedDate 2024-04-01 16:20:55 2023-11-09 16:17:28 2023-08-14 07:45:42 2023-05-09 07:50:33 2023-03-02 16:18:49 2022-11-09 07:50:39
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 0 0 0 0 0
costOfRevenue 449 000 460 000 492 000 0 0 0
grossProfit -449 000 -460 000 -492 000 0 0 0
grossProfitRatio 0 0 0 0 0 0
researchAndDevelopmentExpenses 12M 11M 13M 16M 15M 13M
generalAndAdministrativeExpenses 6394.000 6M 7M 7M 8M 7M
sellingAndMarketingExpenses 6M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 6M 6M 7M 7M 8M 7M
otherExpenses 0 613 000 761 000 880 000 701 000 0
operatingExpenses 18M 17M 20M 24M 23M 20M
costAndExpenses 18M 17M 20M 24M 23M 20M
interestIncome 0 0 200.000 0 0 0
interestExpense 100 000 200 000 200 000 -1M -701 000 -416 000
depreciationAndAmortization 449 000 460 000 492 000 499 000 489 000 473 000
ebitda -18M -17M -20M -24M -23M -20M
ebitdaratio 0 0 0 0 0 0
operatingIncome -18M -17M -20M -24M -23M -20M
operatingIncomeRatio 0 0 0 0 0 0
totalOtherIncomeExpensesNet 475 000 613 000 761 000 880 000 701 000 416 000
incomeBeforeTax -18M -17M -19M -23M -22M -20M
incomeBeforeTaxRatio 0 0 0 0 0 0
incomeTaxExpense 0 0 0 -1M -701 000 -416 000
netIncome -18M -17M -19M -21M -22M -19M
netIncomeRatio 0 0 0 0 0 0
eps -0.640 -0.610 -0.700 -0.780 -0.790 -0.710
epsdiluted -0.640 -0.610 -0.700 -0.780 -0.790 -0.710
weightedAverageShsOut 28M 28M 27M 27M 27M 27M
weightedAverageShsOutDil 28M 28M 27M 27M 27M 27M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol XLO XLO XLO XLO XLO XLO
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-04-01 2023-11-09 2023-08-14 2023-05-09 2023-03-02 2022-11-09
acceptedDate 2024-04-01 16:20:55 2023-11-09 16:17:28 2023-08-14 07:45:42 2023-05-09 07:50:33 2023-03-02 16:18:49 2022-11-09 07:50:39
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 45M 60M 75M 93M 120M 139M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 45M 60M 75M 93M 120M 139M
netReceivables 0 0 0 0 0 0
inventory 0 0 0 0 0 0
otherCurrentAssets 3M 5M 3M 4M 4M 3M
totalCurrentAssets 48M 64M 78M 93M 124M 142M
propertyPlantEquipmentNet 11M 12M 12M 13M 13M 13M
goodwill 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0
longTermInvestments 2M 2M 2M 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 11 000 169 000 197 000 6M 2M 2M
totalNonCurrentAssets 13M 13M 14M 18M 15M 15M
otherAssets 0 0 0 0 0 0
totalAssets 61M 78M 92M 112M 139M 157M
accountPayables 1M 1M 945 000 2M 3M 2M
shortTermDebt 4M 6M 8M 8M 8M 6M
taxPayables 0 0 0 0 0 0
deferredRevenue 0 9M 7M 0 0 0
otherCurrentLiabilities 10M 68 000 82 000 7M 10M 9M
totalCurrentLiabilities 16M 17M 16M 16M 21M 17M
longTermDebt 8142.000 8M 9M 10M 12M 14M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 8M 0 7000.000 26 000 45 000 7M
totalNonCurrentLiabilities 8M 8M 9M 11M 12M 14M
otherLiabilities 1.000 0 0 0 0 0
capitalLeaseObligations 8M 9M 10M 10M 10M 10M
totalLiabilities 24M 25M 25M 27M 34M 31M
preferredStock 0 0 0 0 0 0
commonStock 3000.000 3000.000 3000.000 3000.000 3000.000 3000.000
retainedEarnings -326M -308M -291M -272M -249M -227M
accumulatedOtherComprehensiveIncomeLoss 0 0.000 0 0 0 0
othertotalStockholdersEquity 362M 360M 358M 357M 355M 353M
totalStockholdersEquity 37M 52M 67M 85M 106M 126M
totalEquity 37M 52M 67M 85M 106M 126M
totalLiabilitiesAndStockholdersEquity 61M 78M 92M 112M 139M 157M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 61M 78M 92M 112M 139M 157M
totalInvestments 2M 2M 2M 0 0 0
totalDebt 13M 14M 17M 18M 20M 20M
netDebt -32M -45M -59M -75M -100M -119M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol XLO XLO XLO XLO XLO XLO
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-04-01 2023-11-09 2023-08-14 2023-05-09 2023-03-02 2022-11-09
acceptedDate 2024-04-01 16:20:55 2023-11-09 16:17:28 2023-08-14 07:45:42 2023-05-09 07:50:33 2023-03-02 16:18:49 2022-11-09 07:50:39
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -18M -17M -19M -23M -22M -20M
depreciationAndAmortization 449 000 460 000 492 000 499 000 489 000 473 000
deferredIncomeTax -1M 1000.000 2000.000 0 0 0
stockBasedCompensation 1930.000 2M 2M 2M 2M 2M
changeInWorkingCapital 2M 1M 400 000 -5M 2M -3M
accountsReceivables 0 0 0 0 0 0
inventory 0 0 0 0 0 0
accountsPayables -438 000 542 000 -809 000 -1M 1M 245 000
otherWorkingCapital 2M 492 000 1M 1M 423 000 -3M
otherNonCashItems 3M 23 000 87 000 31 000 59 000 59 000
netCashProvidedByOperatingActivities -13M -13M -17M -25M -18M -20M
investmentsInPropertyPlantAndEquipment 0 0 -316 000 -170 000 -509 000 -333 000
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 -316 000 -170 000 -509 000 -333 000
debtRepayment -2M -2M -1M -2M -21 000 -22 000
commonStockIssued 54 000 8000.000 140 000 0 0 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 54.000 8.000 -992.000 0 0 0
netCashUsedProvidedByFinancingActivities -2M -2M -992 000 -2M -21 000 -22 000
effectOfForexChangesOnCash 0 0 23M 0 0 0
netChangeInCash -15M -16M -18M -27M -19M -20M
cashAtEndOfPeriod 45M 61M 77M 95M 122M 141M
cashAtBeginningOfPeriod 60M 77M 95M 122M 141M 161M
operatingCashFlow -13M -13M -17M -25M -18M -20M
capitalExpenditure 0 0 -316 000 -170 000 -509 000 -333 000
freeCashFlow -13M -13M -17M -25M -19M -20M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-04-01 20:05 ET
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
2024-03-28 11:05 ET
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
2024-03-28 11:00 ET
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
2024-03-28 11:00 ET
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
2024-02-28 21:01 ET
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
2024-01-31 21:01 ET
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
2024-01-08 12:30 ET
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
2023-12-07 12:30 ET
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
2023-11-09 21:01 ET
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
2023-11-03 16:00 ET
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
2023-10-31 13:15 ET
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
2023-09-27 21:02 ET
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
2023-09-05 12:30 ET
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
2023-09-05 11:30 ET
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-14 11:30 ET
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
2023-08-03 20:05 ET
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
2023-05-25 21:01 ET
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
2023-05-09 11:30 ET
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
2023-04-03 20:05 ET
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-03-02 21:05 ET
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
2023-02-27 12:30 ET
Xilio Therapeutics to Present at Upcoming Investor Conferences
2023-02-16 12:30 ET
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit
2023-02-02 12:30 ET
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
2022-11-23 12:30 ET
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12
2022-11-09 12:30 ET
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
2022-11-04 11:30 ET
Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ Summit
2022-09-22 20:05 ET
Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
2022-09-15 20:05 ET
Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors
2022-09-06 20:05 ET
Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-09 11:30 ET
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results
2022-06-16 11:30 ET
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President
2022-05-18 11:30 ET
Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference
2022-05-17 11:30 ET
Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer
2022-05-12 11:30 ET
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results
2022-04-07 10:30 ET
Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
2022-03-01 11:30 ET
Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
2022-02-28 11:30 ET
Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference
2022-02-03 11:30 ET
Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day
2022-01-20 12:30 ET
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors
2022-01-06 12:30 ET
Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors
2021-12-02 12:30 ET
Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results
2021-11-12 12:00 ET
Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting
2021-10-26 20:05 ET
Xilio Therapeutics Announces Closing of Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2024-04-01 16:20 ET
Xilio Therapeutics, Inc. reported for 2023 q4
SEC form 10
2024-04-01 00:00 ET
Xilio Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-04-01 00:00 ET
Xilio Therapeutics, Inc. published news for 2024 q1
SEC form 8
2024-04-01 00:00 ET
Xilio Therapeutics, Inc. published news for 2024 q1
SEC form 10
2023-11-09 16:17 ET
Xilio Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Xilio Therapeutics, Inc. reported for 2023 q3
SEC form 8
2023-11-09 00:00 ET
Xilio Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-08-14 07:45 ET
Xilio Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-08-14 07:40 ET
Xilio Therapeutics, Inc. reported for 2023 q2
SEC form 8
2023-08-14 00:00 ET
Xilio Therapeutics, Inc. reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Xilio Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-08-07 16:09 ET
Xilio Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-08-03 16:15 ET
Xilio Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-06-13 16:05 ET
Xilio Therapeutics, Inc. published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Xilio Therapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Xilio Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-04-25 16:05 ET
Xilio Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-04-03 16:07 ET
Xilio Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-04-03 16:05 ET
Xilio Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-03-02 16:18 ET
Xilio Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-02 16:16 ET
Xilio Therapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-02 00:00 ET
Xilio Therapeutics, Inc. reported for 2022 q4
SEC form 8
2023-03-02 00:00 ET
Xilio Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-01-09 08:30 ET
Xilio Therapeutics, Inc. published news for 2022 q4
SEC form 6
2022-12-23 16:30 ET
Xilio Therapeutics, Inc. published news for 2022 q3
SEC form 6
2022-11-16 16:16 ET
Xilio Therapeutics, Inc. published news for 2022 q3
SEC form 10
2022-11-09 07:50 ET
Xilio Therapeutics, Inc. reported for 2022 q3
SEC form 6
2022-11-09 07:45 ET
Xilio Therapeutics, Inc. reported for 2022 q3
SEC form 8
2022-11-09 00:00 ET
Xilio Therapeutics, Inc. reported for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Xilio Therapeutics, Inc. reported for 2022 q3
SEC form 6
2022-09-16 16:50 ET
Xilio Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-09-15 16:15 ET
Xilio Therapeutics, Inc. published news for 2022 q2
SEC form 10
2022-08-09 07:47 ET
Xilio Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-08-09 07:36 ET
Xilio Therapeutics, Inc. reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Xilio Therapeutics, Inc. reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Xilio Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-07-28 17:07 ET
Xilio Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-06-17 16:06 ET
Xilio Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-06-16 07:45 ET
Xilio Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-06-13 16:30 ET
Xilio Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-12 07:40 ET
Xilio Therapeutics, Inc. reported for 2022 q1
SEC form 6
2022-05-12 07:36 ET
Xilio Therapeutics, Inc. published news for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Xilio Therapeutics, Inc. reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Xilio Therapeutics, Inc. reported for 2022 q1
SEC form 6
2022-04-26 16:05 ET
Xilio Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-03-01 16:07 ET
Xilio Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-03-01 08:00 ET
Xilio Therapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-01 00:00 ET
Xilio Therapeutics, Inc. published news for 2021 q4
SEC form 8
2022-03-01 00:00 ET
Xilio Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-02-04 07:30 ET
Xilio Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-01-06 18:40 ET
Xilio Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-01-06 07:45 ET
Xilio Therapeutics, Inc. published news for 2021 q4
SEC form 6
2021-12-10 20:33 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-12-02 16:15 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-12-02 08:00 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-12-02 00:00 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 8
2021-12-02 00:00 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-05 18:26 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-28 19:15 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-26 16:30 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-21 21:36 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-21 20:48 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-21 20:46 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-21 20:45 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-21 20:45 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-21 20:44 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-21 20:44 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-21 20:41 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-21 20:40 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-21 20:40 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-21 20:39 ET
Xilio Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-21 20:38 ET
Xilio Therapeutics, Inc. published news for 2021 q3